(Q53412719)

14 May 2018

editorial

0 references

title

Is cisplatin still the best platinum compound in non-small-cell lung cancer? (English)

1 reference

14 May 2018

1 reference

J-C Soria

1

1 reference

14 May 2018

T Le Chevalier

series ordinal

2

1 reference

14 May 2018

publication date

1 October 2002

1 reference

14 May 2018

published in

Annals of Oncology

1 reference

14 May 2018

volume

13

1 reference

14 May 2018

page(s)

1515-1517

1 reference

14 May 2018

issue

10

1 reference

14 May 2018

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Pathobiology training for basic scientists

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Cisplatin nephrotoxicity. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDF331

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDF331

1 reference

14 May 2018

PubMed ID

12377638

1 reference

14 May 2018